Prom1 has been utilized extensively to identify and enrich CSCs from many tumors, including lung cancers, colon cancers, hepatocellular carcinomas, and brain tumors [2]–[6], using the specific anti-Prom1 antibody that recognizes the glycosylated-form of Prom1 [7]. Here, PROM1 is linked to colonic neoplasm.